A photo of Bruce Trapnell.

Director, Translational Pulmonary Science Center

Attending Physician, Pulmonologist - Research, Adult Clinical, Division of Pulmonary Medicine

Professor, UC Department of Pediatrics



Board Certified

My Biography & Research


Dr. Trapnell received his medical degree from the University of Maryland in 1985 and medical residency training at The Ohio State University Hospitals. He completed a fellowship in pulmonary medicine and then served as attending physician and senior attending physician at the Clinical Center of the National Institutes of Health. Subsequently, he served as vice president and director of the Division of Pulmonary and Virology Studies at Genetic Therapy, Incorporated, a subsidiary of Novartis.

In 1997, Dr. Trapnell joined Cincinnati Children’s Hospital Medical Center and is now a professor of Medicine and Pediatrics at the UC College of Medicine. At Cincinnati Children's, he directed Cincinnati’s Cystic Fibrosis Therapeutics Development Network Center for more than a decade and participated in numerous clinical trials as principal investigator including studies leading to FDA-approval of Creon® and Pancreaze®. He established and directs the Rare Lung Diseases Clinical Research Consortium (RLDC) in which a study led by Frank McCormack resulted in FDA approval of Sirolimus® as therapy of Lymphangioleiomyomatosis.

Dr. Trapnell’s research group established that GM-CSF autoantibodies caused the rare lung disease autoimmune pulmonary alveolar proteinosis and established clinical laboratory tests for its diagnosis and identified hereditary pulmonary alveolar proteinosis as a new genetic disease caused by mutations in CSF2RA and CSF2RB. His research group developed a novel type of cell transplantation, pulmonary macrophage transplantation, and is currently translating it for testing as therapy in patients with the disease. The group also contributed to the identification, characterization, and methods for diagnosis of indium-related lung disease.

An ardent patient advocate, Dr. Trapnell has worked with patient foundations for cystic fibrosis (CF), alpha-1-antitrypsin deficiency, pulmonary alveolar proteinosis, lymphangioleiomyomatosis, and childhood interstitial lung diseases. He has served as past scientific director for the Alpha-1 Foundation and as co-founder and current scientific director of the Pulmonary Alveolar Proteinosis Foundation. Since coming to Cincinnati, he has provided training in basic, clinical, and translational research at pre- and post-doctoral levels.

Clinical Interests

Research on rare lung diseases including pulmonary alveolar proteinosis; cystic fibrosis; alpha-1 antitrypsin deficiency; lymphangioleiomyomatosis

Research Interests

Alveolar macrophage function; molecular techniques using gene knockout, transgenic and conditional gene expression mouse models and non-human primates, in vitro and in vivo viral gene transfer, and bone marrow transplantation

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Pulmonary Medicine, Cystic Fibrosis Center

Research Divisions

Pulmonary Biology

Blog Posts

Doctors Find Drug for Lethal Lung Disease After Decades of Trying

Rare Diseases

Doctors Find Drug for Lethal Lung Disease After Decades of Trying

Bruce C. Trapnell, MS, MD9/7/2020

Statins Effective in Treating Pulmonary Alveolar Proteinosis

Heart and Lung

Statins Effective in Treating Pulmonary Alveolar Proteinosis

Bruce C. Trapnell, MS, MD7/1/2019

Macrophage Transplantation Could Take Familial PAP Off the Map

Rare Diseases

Macrophage Transplantation Could Take Familial PAP Off the Map

Bruce C. Trapnell, MS, MD6/28/2019

My Education

BS: Biochemistry, University of Maryland, College Park, MD, 1978.

MS: Genetics, The George Washington University, Washington, DC, 1981.

MD: University of Maryland School of Medicine, Baltimore, MD, 1984.

Residency: Internal Medicine, The Ohio State University Hospitals, Columbus, OH, 1987.

Fellowship: Pulmonary Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, 1989.

Certification: Diplomat in Internal Medicine, American Board of Internal Medicine, 1987; Diplomat, National Board of Medical Examiners, 1987; Diplomat in Pulmonary Medicine, American Board of Internal Medicine, 2000.

My Publications

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Cremer, PC; Abbate, A; Hudock, K; McWilliams, C; Mehta, J; Chang, SY; Sheng, CC; Van Tassell, B; Bonaventura, A; Vecchié, A; et al. The Lancet. Rheumatology. 2021; 3:e410-e418.

Whole-Lung Lavage. Towe, C; Trapnell, B. Diagnostic and Interventional Bronchoscopy in Children. 2021.

Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. Trapnell, BC; Inoue, Y; Bonella, F; Morgan, C; Jouneau, S; Bendstrup, E; Campo, I; Papiris, SA; Yamaguchi, E; Cetinkaya, E; et al. New England Journal of Medicine. 2020; 383:1635-1644.

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. De Luca, G; Cavalli, G; Campochiaro, C; Della-Torre, E; Angelillo, P; Tomelleri, A; Boffini, N; Tentori, S; Mette, F; Farina, N; et al. The Lancet. Rheumatology. 2020; 2:e465-e473.

Neutrophil extracellular traps activate IL-8 and IL-1 expression in human bronchial epithelia. Hudock, KM; Collins, MS; Imbrogno, M; Snowball, J; Kramer, EL; Brewington, JJ; Gollomp, K; McCarthy, C; Ostmann, AJ; Kopras, EJ; et al. American Journal of Physiology - Lung Cellular and Molecular Physiology. 2020; 319:L137-L147.

CO0001 MAVRILIMUMAB IMPROVES OUTCOMES IN SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPER-INFLAMMATION. De Luca, G; Cavalli, G; Campochiaro, C; Della Torre, E; Angelillo, P; Tomelleri, A; Boffini, N; Tentori, S; Mette, F; Rovere-Querini, P; et al. Annals of the Rheumatic Diseases. 2020; 79:213-213.

Effective hematopoietic stem cell-based gene therapy in a murine model of hereditary pulmonary alveolar proteinosis. Hetzel, M; Lopez-Rodriguez, E; Mucci, A; Ha Nguyen, AH; Suzuki, T; Shima, K; Buchegger, T; Dettmer, S; Rodt, T; Bankstahl, JP; et al. Haematologica. 2020; 105:1147-1157.

A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment. Applequist, J; Burroughs, C; Jr, RA; Merkel, PA; Rothenberg, ME; Trapnell, B; Desnick, RJ; Sahin, M; Krischer, JP. BMC Medical Research Methodology. 2020; 20.

Increased Pulmonary GM-CSF Causes Alveolar Macrophage Accumulation. Mechanistic Implications for Desquamative Interstitial Pneumonitis. Suzuki, T; McCarthy, C; Carey, BC; Borchers, M; Beck, D; Wikenheiser-Brokamp, KA; Black, D; Chalk, C; Trapnell, BC. American Journal of Respiratory Cell and Molecular Biology. 2020; 62:87-94.

Hospitalization rates among patients with cystic fibrosis using pancreatic enzyme replacement therapy. Trapnell, BC; Chen, S; Khurmi, R; Bodhani, A; Kapoor, M; Haupt, M. Chronic Respiratory Disease. 2020; 17.